Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Opendoor Technologies Inc (OPEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Opendoor Technologies Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287 (market cap $39.89B), while Opendoor Technologies Inc trades at $4.59 (market cap $4.60B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 8.7× Opendoor Technologies Inc's market cap, and Opendoor Technologies Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | OPEN | |
|---|---|---|
Market Cap | $39.89B | $4.60B |
Sector | Health | Real Estate |
52-Week High | $491.22 | $10.52 |
52-Week Low | $278.09 | $0.78 |
Enterprise Value | $38.15B | $4.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Opendoor Technologies (OPEN) trades at $4.764, down 10.11% today, with a market cap around $4.8B. Technicals show a bullish moving average signal but overbought RSI levels, while fundamentals reveal declining revenue ($4.37B in 2025) and deep losses (net margin -35.25%). Recent news highlights CEO leadership changes and AI-driven operational shifts, including India exit to cut costs.
Outlook remains challenging due to persistent unprofitability and high debt, though analyst consensus leans Hold (65.39%). Key risks include housing market sensitivity and execution of new business model; potential upside hinges on margin improvement and seasonal housing rebounds in late 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Opendoor Technologies Inc
Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →
